ABBV vs FMS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.
FMS presents a classic deep-value opportunity, characterized by a stable Piotroski F-Score of 6/9 and a current price ($22.77) trading significantly below both its Graham Number ($35.27) and Intrinsic Value ($58.12). While top-line revenue growth is stagnant (-0.30%), the company has demonstrated a massive recovery in earnings and maintains a sustainable dividend payout ratio of 42.76%. The valuation is exceptionally attractive with a Forward P/E of 5.62 and a Price/Book of 0.81. However, the bullish value thesis is countered by a completely bearish technical trend and weak insider sentiment, suggesting a 'value trap' risk if revenue does not stabilize.
Compare Another Pair
Related Comparisons
ABBV vs FMS: Head-to-Head Comparison
This page compares AbbVie Inc. (ABBV) and Fresenius Medical Care AG (FMS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.